Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus in Ataxia-Telangiectasia
NCT07820579Phase 2Completed
- Start
- Jul 2024
- Primary completion
- May 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in ataxia-telangiectasia (AT). Primary endpoint: Adverse effects and laboratory safety after treatment at 6 months. Started Jul 2024; status: completed.
02
Drugs
sirolimus
03
Conditions
ataxia-telangiectasia (AT)
Beyond the preview
Go deeper on NCT07820579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07820579.